These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31988101)

  • 1. Pharmacodynamics of Meropenem against Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.
    Sabet M; Tarazi Z; Griffith DC
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988101
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant
    Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB
    Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations.
    Macvane SH; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2014; 58(1):599-601. PubMed ID: 24165174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.
    Sabet M; Tarazi Z; Griffith DC
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
    Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Shigemi A; Umezaki Y; Nakamura K; Ueno K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Jun; 43(6):547-52. PubMed ID: 24796218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
    Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
    Dudhani RV; Turnidge JD; Nation RL; Li J
    J Antimicrob Chemother; 2010 Sep; 65(9):1984-90. PubMed ID: 20573659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.
    Smith NM; Lenhard JR; Boissonneault KR; Landersdorfer CB; Bulitta JB; Holden PN; Forrest A; Nation RL; Li J; Tsuji BT
    Clin Microbiol Infect; 2020 Sep; 26(9):1207-1213. PubMed ID: 32061797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
    Turk Dagi H; Kus H; Arslan U; Tuncer I
    Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Almarzoky Abuhussain SS; Avery LM; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
    Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
    J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.
    Zhou J; Ledesma KR; Chang KT; Abodakpi H; Gao S; Tam VH
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant
    Mohd Sazlly Lim S; Heffernan AJ; Roberts JA; Sime FB
    Microb Drug Resist; 2021 Apr; 27(4):546-552. PubMed ID: 32898467
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an
    Beganovic M; Daffinee KE; Luther MK; LaPlante KL
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318006
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.
    Li X; Wang L; Zhang XJ; Yang Y; Gong WT; Xu B; Zhu YQ; Liu W
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6773-81. PubMed ID: 25182633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models.
    Monogue ML; Sakoulas G; Nizet V; Nicolau DP
    Pharmacology; 2018; 101(5-6):255-261. PubMed ID: 29533955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
    Fan B; Guan J; Wang X; Cong Y
    PLoS One; 2016; 11(6):e0157757. PubMed ID: 27315107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.